The Effects of Cinacalcet in Older and Younger Patients on Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial
Patrick S Parfrey, Tilman B Drueeke, Geoffrey A Block, Ricardo Correa-Rotter, Juergen Floege, Charles A Herzog, Gerard M London, Kenneth W Mahaffey, Sharon M Moe, David C Wheeler, Yumi Kubo, Bastian Dehmel, William G Goodman, Glenn M Chertow
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY | AMER SOC NEPHROLOGY | Published : 2015
BACKGROUND AND OBJECTIVES: The calcimimetic cinacalcet reduced the risk of death or cardiovascular (CV) events in older, but not younger, patients with moderate to severe secondary hyperparathyroidism (HPT) who were receiving hemodialysis. To determine whether the lower risk in younger patients might be due to lower baseline CV risk and more frequent use of cointerventions that reduce parathyroid hormone (kidney transplantation, parathyroidectomy, and commercial cinacalcet use), this study examined the effects of cinacalcet in older (≥65 years, n=1005) and younger (3-fold higher in younger relative to older patients and were more frequent in patients randomized to placebo. In older patients,..View full abstract
The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) trial was funded by Amgen.